谷歌浏览器插件
订阅小程序
在清言上使用

An Open-Label, Multicenter Study Investigating RP3 Oncolytic Immunotherapy in Combination with First- or Second-Line Systemic Atezolizumab Plus Bevacizumab in Patients with Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma.

JOURNAL OF CLINICAL ONCOLOGY(2024)

引用 0|浏览3
暂无评分
关键词
283-424-425,281-318-430,3282-270-9760,261-566-11347,298-145-222-184-4809-5347,281-318-430,3282-3306-2822,613-135-244-3829-325,182,1854,3604,3604,38092-26716
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要